

VI. Literatur

- ¹ **Peto**, R. (1975): Cancer and ageing in mice and men. *Br. J. Cancer* 32: 411-426.
- ² **Dix**, D. (1989): The role of aging in cancer incidence: an epidemiological study. *Biological sciences* 44: 10-18.
- ³ **Miller**, D.G. (1980): On the nature of susceptibility to cancer. *Cancer* 46: 1307-1318.
- ⁴ **Nowell**, P.C. (1976): The clonal evolution of tumor cell population. *Science* 194: 23-28.
- ⁵ **Weinberg**, R.A. (1989): Oncogenes, Antioncogenes, and the molecular basis of multistep carcinogenesis. *Cancer Res.* 49: 3713-3721.
- ⁶ **Fearon**, E.R., Vogelstein, B. (1990): A genetic model for colorectal tumorigenesis. *Cell* 61: 759-767.
- ⁷ **Bishop**, J.M. (1987): The molecular genetics of cancer. *Science* 235: 305-311.
- ⁸ **Croce**, M.C. (1986): Chromosome translocations and human cancer. *Cancer Res.* 46: 6019-6023.
- ⁹ **Knudson**, A.G. (1985): Hereditary cancer, oncogenes, and antioncogenes. *Cancer Res.* 45: 1437-1443.
- ¹⁰ **Murphree**, A.L., Benedict, W.F. (1984): Retinoblastoma: clues to human oncogenesis. *Science* 223: 1028-1033.
- ¹¹ **Hansen**, M.F. und Webster, K. Cavenee (1987): Genetics of cancer predisposition. *Cancer Res.* 47: 5518-5527.
- ¹² **Muto**, T., Bussey, H.J.R. und Morson, B.C. (1975): The evolution of cancer of the colon and rectum. *Cancer* 36: 2251-2270.
- ¹³ **Williams**, A.C., Harper, S.J. und Paraskeva, C. (1990): Neoplastic transformation of a human colonic epithelial cell line: in vitro evidence for the adenoma to carcinoma sequence. *Cancer Res.* 50: 4724-4730.
- ¹⁴ **Bodmer**, W.F., Bailey, C.J., Bodmer, J., Bussey, H.J.R., Ellis, A., Gorman, P., Lucibello, F.C., Murday, V.A., Rider, S.H., Scambler, P., Sheer, D., Solomon, E. und Spurr, N.K. (1987): Localization of the gene for familial adenomatous polyposis on chromosome 5. *Nature* 328: 614-619.
- ¹⁵ **Powell**, S.M., Zilz, N., Beazer-Barclay, Y., Bryan, T.M., Hamilton, S.R., Thibodeau, S.N., Vogelstein, B. und Kinzler, K.W. (1992): APC mutations occur early during colorectal tumorigenesis. *Nature* 359: 235-237.
- ¹⁶ **Vogelstein**, B., Fearon, E.R., Hamilton, S.R., Kern, S.E., Preisinger, A.C., Leppert, M., Nakamura, Y., White, R., Smits, A.M.M., Bos, J.L. (1988): Genetic alterations during colorectal-tumor development. *N Engl J Med* 319: 525-532.
- ¹⁷ **Nishisho**, I., Nakamura, Y., Miyoshi, Y., Miki, Y., Ando, H., Horii, A., Koyama, K., Utsunomiya, J., Baba, S., Hedge, P., Markham, A., Krush, A.J., Petersen, G., Hamilton, S.R., Nilbert, M.C., Levy, D.B., Bryan, T.M., Preisinger, A.C., Smith, K.J., Su, L.-K., Kinzler, K.W., Vogelstein, B. (1991): Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. *Science* 253: 665-669.
- ¹⁸ **Cho**, K.R., Vogelstein, B. (1992): Suppressor gene alterations in the colorectal adenoma-carcinoma sequence. *J. Cell. Biochem., Suppl.* 16G: 137-141.
- ¹⁹ **Razin**, A., Kafri, T. (1994): DNA methylation from embryo to adult. *Progr. Nucl. Acid Res. Mol. Biol.* 48: 53-81.
- ²⁰ **Ferguson**, A.T., Lapidus, R.G., Baylin, S.B., Davidson, N.E. (1995): Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. *Cancer Res.* 55: 2279-2283.
- ²¹ **Feinberg**, A.P., Gehrke, C.W., Kuo, K.C., und Ehrlich, M. (1988): Reduced genomic 5-methylcytosine content in human colonic neoplasia. *Cancer Research* 48: 1159-1161.

-
- ²² **Schmid, M., Haaf, T. und Grunert, D. (1984):** 5-azacytidine-induced undercondensations in human chromosomes. *Human Genet.* 67: 257-263.
- ²³ **Bos, J.L., Fearon, E.R., Hamilton, S.R., Verlaan-de Vries, M., van Boom, J.H., van der Eb, A.J., Vogelstein, B. (1987):** Prevalence of ras gene mutations in human colorectal cancers. *Nature* 327: 293-297.
- ²⁴ **Forrester, K., A. moguera, C., Han, K., Grizzle, W.E., Perucho, M. (1987):** Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. *Nature* 327: 298-303.
- ²⁵ **Bos, J.L. (1995):** p21ras: An oncoprotein functioning in growth factor-induced signal transduction. *Eur J Cancer* 31A: 1051-1054.
- ²⁶ **Ookawa, K., Sakamoto, M., Hirohashi, S., Yoshida, Y., Sugimura, T., Terada, M., Yokota, J. (1993):** Concordant p53 and DCC alterations and allelic losses on chromosomes 13q and 14q associated with liver metastases of colorectal carcinoma. *Int. J. Cancer* 53: 382-387.
- ²⁷ **Hedrick, L., Cho, K.R., Fearon, E.R., Wu, T.-C., Kinzler, K.W., Vogelstein, B. (1994):** The DCC gene product in cellular differentiation and colorectal tumorigenesis. *Gen Devel* 8: 1174-1183.
- ²⁸ **Harris, C.C. (1996):** p53 tumor suppressor gene: from the basic research laboratory to the clinic-an abridged historical perspective. *Carcinogenesis* 17: 1187-1198.
- ²⁹ **Baker, S.J., Fearon, E.R., Nigro, J.J., Hamilton, S.R., Preisinger, A.C., Jessup, J.M., VanTuinen, P., Ledbetter, D.H., Barker, D.F., Nakamura, Y., White, R., Vogelstein, B. (1989):** Chromosome 17 Deletions and p53 gene mutations in colorectal carcinomas. *Science* 244: 217-221.
- ³⁰ **Baker, S.J., Preisinger, A.C., Jessup, J.M., Paraskeva, C., Markowitz, S., Willson, J.K.V., Hamilton, S., Vogelstein, B. (1990):** p53 gene mutation occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. *Cancer Res.* 50: 7717-7722.
- ³¹ **Nigro, J.M., Baker, S.J., Preisinger, A.C., Jessup, J.M., Hostetter, R., Cleary, K., Bigner, S.H., Davidson, N., Baylin, S., Devilee, P., Glover, T., Collins, F., Weston, A., Modali, R., Harris, C., Vogelstein, B. (1989):** Mutations in the p53 gene occur in diverse human tumour types. *Nature* 342: 705-708.
- ³² **Malkin, D. Li, F.P., Strong, L.C., Fraumeni, J.F., Nelson, C.E., Kim, D.H., Kassel, J., Gryka, M.A., Bischoff, F.Z., Tainsky, M.A. (1990):** Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. *Science* 250: 1233-1238.
- ³³ **Kleihues, P., Schäuble, B., zur Hausen, A., Estève, J., Ohgaki, H. (1997):** Tumors associated with p53 germline mutations. *Am J Pathol* 150: 1-13.
- ³⁴ **Donehower, L.A., Harvey, M., Slagle, B.L., McArthur, M.J., Montgomery, C.A., Butel, J.S., Bradley, A. (1992):** Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. *Nature* 356: 215-221.
- ³⁵ **Kastan, M.B., Onyekwere, O., Sidransky, D., Vogelstein, B. und Craig, R.W. (1991):** Participation of p53 protein in the cellular response to DNA damage. *Cancer Res.* 51: 6304-6311.
- ³⁶ **Graeber, T.G., Osmanian, C., Jacks, T., Housman, D.E., Koch, C.J., Lowe, S.W., Giaccia, A.J. (1996):** Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. *Nature* 379: 88-91.
- ³⁷ **Linke, S.P., Clarkin, K.C., Di Leonardo, A., Tsou, A., Wahl, G.M. (1996):** A reversible, p53-dependent G₀/G₁ cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. *Genes & Development* 10: 943-947.
- ³⁸ **Kastan, M.B., Zhan, Q., El-Deiry, W.S., Carrier, F., Jacks, T., Walsh, W.V., Plunkett, B.S., Vogelstein, B. und Fornace, A.J. (1992):** A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. *Cell* 71: 587-597.
- ³⁹ **Selvakumaran, M., Lin, H.-K., Miyashita, T., Wang, H.G., Krajewski, S., Reed, J.C., Hoffman, B., Liebermann, D. (1994):** Immediate early up-regulation of bax expression by p53 but not TGF β 1: a paradigm for distinct apoptotic pathways. *Oncogene* 9: 1791-1798.

-
- ⁴⁰ **Zhan, Q.**, Fan, S., Bae, I., Guillouf, C., Liebermann, D.A., O'Connor, P., Fornace, A.J. (1994): Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. *Oncogene* 9: 37
- ⁴¹ **Miyashita, T.**, Krajewski, S., Krajewska, M., Wang, H.G., Lin, H.K., Liebermann, K.A., Hoffman, B., Reed, J.C. (1994): Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. *Oncogene* 9: 1799-1805.
- ⁴² **Kuerbitz, S.J.**, Plunkett, B.S., Walsh, W.V., Kastan, M.B. (1992): Wild-type p53 is a cell cycle checkpoint determinant following irradiation. *Proc. Natl. Acad. Sci. USA* 89: 7491-7495.
- ⁴³ **Lane, D.P.**, Crawford, L.V. (1979): T antigen is bound to a host protein in SV40-transformed cells. *Nature* 278: 261-263.
- ⁴⁴ **Linzer, D.I.H.**, Levine, A.J. (1979): Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. *Cell* 17: 43-52.
- ⁴⁵ **Bartek, J.**, Iggo, R., Gannon, J., Lane, D.P. (1990): Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. *Oncogene* 5: 893-899.
- ⁴⁶ **Midgley, C.A.**, Lane, D.P. (1997): p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. *Oncogene* 15: 1179-1189.
- ⁴⁷ **Neutra, M.R.**, Forstner, J.F. (1987): Gastrointestinal mucus: synthesis, secretion, and function. In: Physiology of the gastrointestinal tract, second edition, ed. Johnson, L.R., Raven Press New York 1987: 975-1009.
- ⁴⁸ **Hilkens, J.**, Ligtenberg, M.J.L., Vos, H.L., Litvinov, S.V. (1992): Cell membrane-associated mucins and their adhesion-modulating property. *TIBS* 17: 359-363.
- ⁴⁹ **Shimizu, Y.**, Shaw, S. (1993): Mucins in the mainstream. *Nature* 366: 630-631.
- ⁵⁰ **Springer, G.F.** (1984): T and Tn, General carcinoma autoantigens. *Science* 224: 1198-1206.
- ⁵¹ **Kurosaka, A.**, Kitagawa, H., Fukui, S., Numata, Y., Nakada, H., Funakoshi, I., Kawasaki, T., Ogawa, T., Iijima, H., Yamashina, I. (1988): A monoclonal antibody that recognizes a cluster of a disaccharide, NeuAc α 2 \rightarrow 6GalNAc, in mucin-type glycoproteins. *JBC* 263: 8724-8726.
- ⁵² **Boland, C.R.**, Deshmukh, G.D. (1990): The carbohydrate composition of mucin in colonic cancer. *Gastroenterology* 98: 1170-1177.
- ⁵³ **Girling, A.**, Bartkova, J., Burchell, J., Gendler, S., Gillett, C., Taylor-Papadimitiou, J. (1989): A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas. *Int. J. Cancer* 43: 1072-1076.
- ⁵⁴ **Müller, S.**, Alving, K., Peter-Katalinic, J., Zachara, N., Gooley, A.A., Hanisch, F.-G. (1999): High density O-glycosylation on tandem repeat peptide from secretory MUC1 of T47D breast cancer cells. *JBC* 274: 18165-18172.
- ⁵⁵ **Gum, J.R.** (1992): Mucin genes and the proteins they encode: structure, diversity, and regulation. *Am J Respir Cell Mol Biol* 7: p557-564.
- ⁵⁶ **Gendler, S.J.**, Lancaster, C.A., Taylor-Papadimitriou, J., Duhig, T., Peat, N., Burchell, J., Pemberton, L., Lalani, E.-N., Wilson, D. (1990): Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. *JBC* 265: 15286-15293.
- ⁵⁷ **Ho, S.B.**, Niehans, G.A., Lyftogt, C., Yan, P.S., Cherwitz, D.L., Gum, E.T., Dahiya, R., Kim, Y.S. (1993): Heterogeneity of mucin gene expression in normal and neoplastic tissues. *Cancer Research* 53: 641-651.
- ⁵⁸ **Toribara, N.W.**, Robertson, A.M., Ho, S.B., Kuo, W.-L., Gum, E., Hicks, J.W., Gum, J.R., Byrd, J.C., Siddiki, B., Kim, Y.S. (1993): Human gastric mucin. *JBC* 268: 5879-5885.
- ⁵⁹ **Bobek, L.A.**, Tsai, H., Biesbrock, A.R., Levine, M.J. (1993): Molecular cloning, sequence and specificity of expression of the gene encoding the low molecular weight human salivary mucin. *JBC* 268: 20563ö-20569.

- ⁶⁰ **Lapensee**, L., Paquette, Y., Bleau, G. (1997): Allelic polymorphism and chromosomal localization of the human oviductin gene (MUC9). *Fertil Steril* 68: 702-708.
- ⁶¹ **Griffiths**, B., Matthews, D.J., West, L., Attwood, J., Povey, S., Swallow, D.M., Hum, J.R., Kim, Y.S. (1990): Assignment of the polymorphic intestinal mucin gene (MUC2) to chromosome 11p15. *Ann. Hum Genet.* 54: 277-285.
- ⁶² **Gum**, J.R., Byrd, J.C., Hicks, J.W., Toribara, N.W., Lamport, D.T.A., Kim, Y.S. (1989): Molecular cloning of human intestinal mucin cDNAs. *The Journal of biological chemistry* 264: 6480-6487.
- ⁶³ **Gum**, J.R., Hicks, J.W., Toribara, N.W., Siddiki, B., Kim, Y.S. (1994): Molecular cloning of human intestinal mucin (MUC2) cDNA. *The Journal of biological Chemistry* 269: 2440-2446.
- ⁶⁴ **Byrd**, J.C., Nerdelli, J., Siddiqui, B., Kim, Y.S. (1988): Isolation and characterization of colon cancer mucin from xenografts of LS174T cells. *Cancer Res* 48: 6678-6685.
- ⁶⁵ **Tytgat**, K.M.A., Büller, H.A., Opdam, F.J.M., Kim, Y.S., Einerhand, A.W.C., Dekker, J. (1994): Biosynthesis of human colonic mucin: Muc2 is the prominent secretory mucin. *Gastroenterology* 107: 1352-1363.
- ⁶⁶ **Gambus**, G., de Bolos, C., Andreu, D., Franci, C., Egea, G., Real, F.X. (1993): Detection of the MUC2 apomucin tandem repeat with a mouse monoclonal antibody. *Gastroenterology* 104: 93-102.
- ⁶⁷ **Blank**, M., Klusmann, E., Krüger-Krasagakes, S., Schmitt-Gräff, A., Stolte, M., Bornhoeft, G., Stein, H., Xing, P.-X., McKenzie, I.F.C., Verstijnen, C.P.H.J. (1994): Expression of MUC2-mucin in colorectal adenomas and carcinomas of different histological types. *Int. J. Cancer* 59: 301-306.
- ⁶⁸ **Ogata**, S., Uehara, H., Chen, A., Itzkowitz, S.H. (1992): Mucin gene expression in colonic tissues and cell lines. *Cancer Res.* 52: 5971-5978.
- ⁶⁹ **Yamashita**, K., Yonezawa, S., Tanaka, S., Shirahama, H., Sakoda, K., Imai, K., Xing, P.-X., McKenzie, I.F.C., Hilkens, J., Kim, Y.S., Sato, E. (1993): Immunohistochemical study of mucin carbohydrates and core proteins in hepatolithiasis and cholangiocarcinoma. *Int. J. Cancer* 55: 82-91.
- ⁷⁰ **Gerard**, C., Eddy, R.L., Shows, T.B. (1990): The core polypeptide of cystic fibrosis tracheal mucin contains a tandem repeat structure. *J. Clin. Invest.* 86: 1921-1927.
- ⁷¹ **Jany**, B.H., Gallup, M.W., Yan, P.-S., Gum, J.R., Kim, Y.S., Basbaum, C.B. (1991): Human bronchus and intestine express the same mucin gene. *J. Clin. Invest.* 87: 77-82.
- ⁷² **Audie**, J.P., Janin, A., Porchet, N., Copin, M.C., Gosselin, B. und Aubert, J.P. (1993): Expression of human mucin genes in respiratory, digestive, and reproductive tracts ascertained by in situ hybridisation. *J. Histochem. Cytochem.* 41: 1479-1485.
- ⁷³ **Balague**, C., Audie, J.-P., Porchet, N., Real, F.X. (1995): In situ hybridization shows distinct patterns of mucin gene expression in normal, benign, and malignant pancreas tissue. *Gastroenterology* 109: 953-964.
- ⁷⁴ **Tashiro**, Y., Yonezawa, S., Kim, Y.S., Sato, E. (1994): Immunohistochemical study of mucin carbohydrates and core proteins in human ovarian tumors. *Hum Pathol* 25: 364-372.
- ⁷⁵ **Melamed**, M.R., Robbins, G.F. und Foote, F.W. (1961): Prognostic significance of gelatinous mammary carcinoma. *Cancer* 4: 699-704.
- ⁷⁶ **Silverberg**, S.G., Kay, S., Chitale, A.R. und Levitt, S.H. (1971): Colloid carcinoma of the breast. *A.J.C.P.* 55: 355-363.
- ⁷⁷ **Sorbe**, B., Frankendal, B. und Veress, B. (1982): Importance of histologic grading in the prognosis of epithelial ovarian cancer. *Obstet Gynecol* 59: 576-582.
- ⁷⁸ **Shepherd**, J.H. : Surgical management of ovarian cancer in: J.H. Shepherd und Monaghan, J.M. (Hg.): Clinical gynaecological oncology. 2.Aufl. 1990, Oxford.

- ⁷⁹ **Randrianjafisamindrakotroka**, N.S., Hedelin, G., Philippe, E. und Schaffer, P. (1995): Carcinomes ovariens. *J. Gynecol. Obstet. Biol. Reprod.* 24: 711-716.
- ⁸⁰ **Yamamoto**, M., Saitoh, Y. und Hermanek, P.: Exocrine pancreatic carcinoma. In: Prognostic factors in cancer. Hg.: Hermanek, P., Gospodarowicz, M.K., Henson, D.E., Hutter, R.V.P. und Sobin, L.H. Springer Verlag 1995.
- ⁸¹ **Symonds**, D.A. und Vickery, A.L. (1976): Mucinous carcinoma of the colon and rectum. *Cancer* 37: 1891-1900.
- ⁸² **Umpleby**, H.C., Ranson, D.L. und Williamson, R.C.N. (1985): Peculiarities of mucinous colorectal carcinoma. *Br. J. Surg.* 72: 715-718.
- ⁸³ **Sundblad**, A.S., Paz, R.A. (1982): Mucinous carcinomas of the colon and rectum and their relation to polyps. *Cancer* 50: 2504-2509.
- ⁸⁴ **Laurent-Puig**, P., Olschwang, S., Delattre, O., Validire, P., Melot, T., Mosseri, V., Salmon, R.J., Thomas, G. (1991): Association of Ki-ras mutation with differentiation and tumor-formation pathways in colorectal carcinoma. *Int. J. Cancer* 49: 220-223.
- ⁸⁵ **Ichikawa**, Y., Nishida, M., Suzuki, H., Yoshida, S., Tsunoda, H., Kubo, T., Uchida, K., Miwa, M. (1994): Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors. *Cancer Res.* 54: 33-35.
- ⁸⁶ **Enomoto**, T., Weghorst, C.M., Inoue, M., Tanizawa, O., Rice, J.M. (1991): K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. *Am J Pathol* 139: 777-785.
- ⁸⁷ **Domagala**, W., Harezga, B., Szadowska, A., Markiewski, M., Weber, K., Osborn, M. (1993): Nuclear p53 protein accumulates preferentially in medullary and high-grade ductal but rarely in lobular breast carcinomas. *Am J Pathol* 142: 669-674.
- ⁸⁸ **Milner**, B.J., Allan, L.A., Eccles, D.M., Kitchener, H.C., Leonard, R.C.F., Kelly, K.F., Parkin, D.E., Haites, N.E. (1993): p53 mutation is a common genetic event in ovarian carcinoma. *Cancer Res.* 53: 2128-2132.
- ⁸⁹ **Hoshi**, T., Imai, M. und Ogawa, K. (1994): Frequent K-ras mutations and absence of p53 mutations in mucin-producing tumors of the pancreas. *J. surg. Oncol.* 55: 84-91.
- ⁹⁰ **Scarpa**, A., Capelli, P., Mukai, K., Zamboni, G., Oda, T., Iacono, C., Hirohashi, S. (1993): Pancreatic adenocarcinomas frequently show p53 gene mutations. *Am J Pathol* 142: 1534-1543.
- ⁹¹ **Hanski**, C., Tiecke, F., Hummel, M., Hanski, M-L., Ogorek, D., Rolfs, A., Schmitt-Gräff, A., Stein, H., Riecken, E.-O. (1996): Low frequency of p53 gene mutations and protein expression in mucinous colorectal carcinomas. *Cancer letters* 103: 163-170.
- ⁹² **Bronner**, C.E., Baker, S.M., Morrison, P.T., Warren, G., Smith, L.G., Lescoe, M.K., Kane, M., Earabino, C., Lipford, J., Lindblom, A., Tannergard, P., Bollag, R.J., Godwin, A.R., Ward, D.C., Nordenskjold, M., Fishel, R., Kolodner, R., Liskay, M.R. (1994): Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. *Nature* 368: 258-261.
- ⁹³ **Mecklin**, J.-P., Sipponen, P., Järvinen, H.J. (1986): Histopathology of colorectal carcinomas and adenomas in cancer family syndrome. *Dis Colon Rectum* 29: 849-853.
- ⁹⁴ **Lynch**, H.T., Lanspa, S., Smyrk, T., Boman, B., Watson, P., Lynch, J. (1991): Hereditary nonpolyposis colorectal cancer (Lynch Syndromes I & II). *Cancer Genet Cytogenet* 53: 143-160.
- ⁹⁵ **Jass**, J.R., Smyrk, T.C., Stewart, S.M., Lane, M.R., Lanspa, S.R., Lynch, H.T. (1994): Pathology of Hereditary Non-Polyposis Colorectal Cancer. *Anticancer Research* 14: 1631-1634.
- ⁹⁶ **Kim**, H., Jen, J., Vogelstein, B., Hamilton, S.R. (1994): Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. *Am J Pathol* 145: 148-156.
- ⁹⁷ **Messerini**, L., Vitelli, F., de Vitis, L., Mori, S., Calzolari, A., Palmirotta, R., Calabro, A., Papi, L. (1997): Microsatellite instability in sporadic mucinous colorectal carcinomas: relationship to clinico-pathological variables. *J. Pathol.* 182: 380-384.

-
- ⁹⁸ **Ajioka, Y., Allison, L.J., Jass, J.R.** (1996): Significance of MUC1 and MUC2 mucin expression in colorectal cancer. *J Clin Pathol* 49: 560-564.
- ⁹⁹ **Chang, S.-K., Dohrman, A.F., Basbaum, C.B., Ho, S.B., Tsuda, T., Toribara, N.W., Hum, J.R., Kim, Y.S.** (1994): Localization of mucin (MUC2 and MUC3) messenger RNA and peptide expression in human normal intestine and colon cancer. *Gastroenterology* 107: 28-36.
- ¹⁰⁰ **Hanski, C., Riede, E., Gratchev, A., Foss, H.-D., Böhm, C., Klußmann, E., Hummel, M., Mann, B., Buhr, H.-J., Stein, H., Kim, Y.S., Gum, J., Riecken, E.-O.** (1997): MUC2 gene suppression in human colorectal carcinomas and their metastases: in vitro evidence of the modulatory role of DNA Methylation. *Lab Invest* 77: 685-695.
- ¹⁰¹ **Komaki, K., Sakamoto, G., Sugano, H., Morimoto, T. und Monken, Y.** (1988): Mucinous carcinoma of the breast in Japan. *Cancer* 61: 989-996.
- ¹⁰² **Norris, H.J., Taylor, H.B.** (1965): Prognosis of mucinous (gelatinous) carcinoma of the breast. *Cancer* 18: 879-885.
- ¹⁰³ **Tabar, L., Fagerberg, G., Chen, H.H., Duffy, S.W. und Gad, A.** (1996): Tumor development, histology and grade of breast cancers: prognosis and progression. *Int. J. Cancer* 66: 413-419.
- ¹⁰⁴ **Rasmussen, B.B., Rose, C. und Christensen, I.** (1987): Prognostic factors in primary mucinous breast carcinoma. *Am J Clin Pathol* 87: 155-160.
- ¹⁰⁵ **Halvorsen, T.B. und Seim, E.** (1988): Influence of mucinous components on survival in colorectal adenocarcinomas: a multivariate analysis. *J Clin Pathol* 41: 1068-1072.
- ¹⁰⁶ **van den Ingh, H.F., Ruiter, D.J., Griffioen, G., van Muijen, G.N.P. und Ferrone, S.** (1987): HLA antigens in colorectal tumours-low expression of HLA class I antigens in mucinous colorectal carcinomas. *Br. J. Cancer* 55: 125-130.
- ¹⁰⁷ **Garrido, F., Cabrera, T., Concha, A., Glew, S., Ruiz-Cabello, F., Stern, P.L.** (1993): Natural history of HLA expression during tumour development. *Immunology today* 14: 491-499.
- ¹⁰⁸ **Möller, P., Momburg, F., Koretz, K., Moldenhauer, G., Herfarth, C., Otto, H.F., Hämmerling, G.J., Schlag, P.** (1991): Influence of major histocompatibility complex class I and II antigens on survival in colorectal carcinoma. *Cancer Res.* 51: 729-736.
- ¹⁰⁹ **Yagita, M., Seppo, A., Renkonen, O., Saksella, E.** (1993): Deacetylase activity of human tumor cells producing immunosuppressive aminosugars: its possible role in resistance to cell-mediated cytotoxicity. *Cancer Res* 53: 5600-5604.
- ¹¹⁰ **Bergelson, L.D.** (1993): Gangliosides and antitumor immunity. *Clin Invest* 71: 590-594.
- ¹¹¹ **Nakagomi, H., Petersson, M., Magnusson, I., Huhlin, C., Matsuda, M., Mellstedt, H., Taupin, J.L., Vivier, E., Anderson, P., Kiessling, R.** (1993): Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK-cells of patients with colorectal carcinoma. *Cancer Res* 53: 5610-5612.
- ¹¹² **Birchard, V., Van Pel, A., Wölfel, T., Löfel, C., De Plaen, E., Lethe, B., Coulie, P., Boon, T.** (1993): The tyrosinase gene codes for an antigen recognized by autologous cytolytic T-lymphocytes on HLA-a2 melanomas. *J. Exp. Med.* 178: 489-495.
- ¹¹³ **Burchell, J., Gendler, S., Taylor-Papadimitriou, J., Girling, A., Lewis, A., Millis, R., Lampert, D.** (1987): Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. *Cancer Res* 47: 5476-5482.
- ¹¹⁴ **Barnd, D.L., Lan, M.S., Metzgar, R.S., Finn, O.J.** (1989): Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. *Proc. Natl. Acad. Sci. USA* 86: 7159-7163.
- ¹¹⁵ **Jerome, K.R., Barnd, D.L., Bendt, K.M., Boyer, C.M., Taylor-Papadimitriou, J., McKenzie, I.F.C., Bast, R.C., Finn, O.J.** (1991): Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. *Cancer Res.* 51: 2908-2916.

- ¹¹⁶ **Ioannides**, C.G., Fisk, B., Jerome,D.r., Irimura,t., Wharton, J.T., Finn, O.J. (1993): Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. *J Immunol* 151: 3693-3703.
- ¹¹⁷ **Böhm**,C.M., Hanski,M.-L., Stefanovic,S., Rammensee,H.G., Stein,H., Taylor-Papadimitriou,J., Riecken,E.-O., Hanski,C. (1998):Identification of HLA-A2-restricted epitopes of the tumor-associated antigen muc2 recognized by human cytotoxic T cells. *Int.J.Cancer* 75: 688-693.
- ¹¹⁸ **Lubin**, R., Schlichtholz,B., Teillaud,J.L., Garay,E., Bussel,A., Wild,C.P., Soussi,T. (1995): p53 antibodies in patients with various types of cancer: assay, identification, and characterization. *Clinical Cancer Research* 1: 1463-1469.
- ¹¹⁹ **Crawford**, L.V., Pim,D.C., Bulbrood,R.D. (1982): Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. *Int. J. Cancer* 30: 403-408.
- ¹²⁰ **Angelopoulou**, K., Diamandis,E.P., Sutherland,D.J.A., Kellen, J.A., Bunting,P.S. (1994): Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. *Int. J. Cancer* 58: 480-487.
- ¹²¹ **Davidoff**, A.M., Iglehart,J.D., Marks,J.R. (1992): Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. *Proc. Natl. Acad. Sci. USA* 89: 3439-3442.
- ¹²² **Winter**, S.J., Minna,J.D., Johnson,B.E., Takahashi,T., Gazdar, A.F., Carbone, D.P. (1992): Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. *Cancer Res.* 52: 4168-4174.
- ¹²³ **Mudenda**, B., Green, J.A., Green, B., Jenkins, J.R., Robertson, L, Tarunina, M., Leinster, S.J. (1994): The relationship between serum p53 autoantibodies and characteristics of human breast cancer. *Br. J. Cancer* 69: 1115-1119.
- ¹²⁴ **Guinee**, D.G., Travis,W.D., Trivers,G.E., De Benedetti, V.M.G., Cawley,H., Welsh, J.A., Bennett,W.P., Jett,J., Colby,T.v., Tazelaar,H., Abbondanzo,S.L., Pairolero,P., Trastek,V., Caporaso,N.E., Liotta, L.A., Harris, C.C. (1995): Gender comparisons in human lung cancer: analysis of p53 mutations, anti-p53 serum antibodies and C-erbB-2 expression. *Carcinogenesis* 16: 993-1002.
- ¹²⁵ **Schlichtholz**, B., Legros,Y., Gillet,D., Gaillard, C., Marty,M., Lane,D., Calvo,F., Soussi,T. (1992): The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. *Cancer Res.* 52: 6380-6384.
- ¹²⁶ **Lubin**, R., Schlichtholz,B., Bengoufa,D., Zalcmán,G., Tredaniel,J., Hirsch,A., Caron de Fromentel, C., Preudhomme,C., Fenaux,P., Fourniet,G., Mangin,P., Laurent-Puig,P., Pelletier,G., Schlumberger,M., Desgrandchamps,F., Le Duc,a., Peyrat,J.P., Janin,N., Bressac,B., Soussi,T. (1993): Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution of primary structure and exposure on protein surface. *Cancer Res.* 53: 5872-5876.
- ¹²⁷ **Labrecque**, S., Naor, N., Thomson, D., Matlashewski,G. (1993): Analysis of the Anti-p53 antibody response in cancer patients. *Cancer Res.* 53: 3468-3471.
- ¹²⁸ **Bargmann**, C.I., Hung, M.-C., Weinberg, R.A. 1986): The neu oncogene encodes an epidermal growth factor receptor-related protein. *Nature* 319: 226-230.
- ¹²⁹ **Disis**, M.L., Calenoff,E., McLaughlin,G., Murphy,A.E., Chen,W., Groner,B., Jeschke,M., Lydon,N., McGlynn,E., Livingston,Z.B., Moe,R., Cheever,M.A. (1994): Existent T-Cell and antibody immunity to HER-2/neu protein in patients with breast cancer. *Cancer Res.* 54: 16-20.
- ¹³⁰ **Erisman**, M.D., Rothberg, P.G., Diehl, R.E., Morse, C.C., Spandorfer, J.M., Astrin, S.M. (1985): Deregulation of c-myc gene expression in human colon carcinoma is not accompanied by amplification of rearrangement of the gene. *Mol Cell Biol* 5: 1969-1976.
- ¹³¹ **Ben-Mahrez**,K., Sorokine,I., Thierry,D., Kawasumi,T., Ishii,S., Salmon,R., Kohiyama,M. (1990): Circulating antibodies against c-myc oncogene product in sera of colorectal cancer patients. *Int. J. Cancer* 46: 35-38.
- ¹³² **Rughetti**, A., Turchi,V., Ghetti, C.A., Scambia,G., Panici,P.B., Roncucci,G., Mancuso,S., Frati,L., Nuti,M. (1993): Human B-cell immune response to the polymorphic epithelial mucin. *Cancer Res.* 53: 2457-2459.

-
- ¹³³ **Kotera**, Y., Fontenot, J.D., Pecher, G., Metzgar, R.S., Finn, O.J. (1994): Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. *Cancer Res.* 54: 2856-2860.
- ¹³⁴ **Azzopardi**, J.G. et al., Histological typing of breast tumours, WHO, Geneva 1981.
- ¹³⁵ **Serov**, S.F. and Scully, R.E., Histological typing of ovarian tumours, WHO, Geneva 1973.
- ¹³⁶ **Jass**, J.J. and Sobin, L.H., Histological typing of intestinal tumours, Springer-Verlag Berlin 1989
- ¹³⁷ **Devine**, P.L., McGuckin, M.A., Birrell, G.W., Whitehead, R.H., Sachdev, G.P., Shield, P., Ward, B.G. (1993): Monoclonal antibodies reacting with the MUC2 mucin core protein. *Br. J. Cancer* 67: 1182-1188.
- ¹³⁸ **Hanski**, C., Bornhoeft, G., Shimoda, T., Hanski, M.-L., Lane, D., Stein, H., Riecken, E.-O. (1992): Expression of p53 protein in invasive colorectal carcinomas of different histologic types. *Cancer* 70: 2772-2777.
- ¹³⁹ **Campo**, E., de la Calle-Martin, O., Miquel, R., Palacin, A., Romero, M., Fabregat, V., Vives, J., Cardesa, A., Yague, J. (1991): Loss of heterozygosity of p53 gene and p53 protein expression in human colorectal carcinomas. *Cancer Res.* 51: 4436-4442.
- ¹⁴⁰ **Costa**, A., Marasca, R., Valentini, B., Savarino, M., Faranda, A., Silvestrini, R., Torelli, G. (1995): p53 gene point mutations in relation to p53 nuclear protein accumulation in colorectal cancers. *J. Pathol.* 176:45-53.
- ¹⁴¹ **Tomoda**, H., Kakeji, Y. (1995): Immunohistochemical analysis of p53 in colorectal cancer regarding clinicopathological correlation and prognostic significance. *J Surg Oncol* 58: 125-128.
- ¹⁴² **Walker**, R.A., Dearing, S.J., Lane, D.P., Varley, J.M. (1991): Expression of p53 protein in infiltrating and in-situ breast carcinomas. *J Pathol* 165: 203-211.
- ¹⁴³ **Marchetti**, A., Buttitta, F., Pellegrini, S., Campagni, D., Diella, F., Cecchetti, D., Callahan, R., Bistocchi, M. (1993): p53 mutations and histological type of invasive breast carcinoma. *Cancer Res.* 53: 4665-4669.
- ¹⁴⁴ **Varley**, J.M., Brammar, W.J., Lane, D.P., Swallow, J.E., Dolan, C., Walker, R.A. (1991): Loss of chromosome 17p13 sequences and mutation of p53 in human breast carcinomas. *Oncogene* 6: 413-421.
- ¹⁴⁵ **Poller**, D.N., Hutchings, C.e., Galea, M., Bell, J.A., Nicholson, R.A., Elston, C.W., Blamey, R.W., Ellis, I.O. (1992): p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor. *Br. J. Cancer* 66: 583-588.
- ¹⁴⁶ **Davidoff**, A.M., Herndon, J.E., Glover, N.S., Kerns, B.-J., Pence, J.C., Iglehart, J.D., Marks, J.R. (1991): Relation between p53 overexpression and established prognostic factors in breast cancer. *Surgery* 110: 259-264.
- ¹⁴⁷ **Schimmelpennig**, H., Eriksson, E.t., Zetterberg, A., Auer, G.U. (1994): Association of immunohistochemical p53 tumor suppressor gene protein overexpression with prognosis in highly proliferative human mammary adenocarcinomas. *World J. Surg.* 18: 827-833.
- ¹⁴⁸ **Baas**, I.O., Mulder, J.-W.R., Offerhaus, G.J.A., Vogelstein, B., Hamilton, S.R. (1994): An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. *J. Pathol.* 172: 5-12.
- ¹⁴⁹ **Renninson**, J., Baker, B.W., McGown, A.T., Murphy, D., Norton, J.D., Fox, B.W., Crowther, D. (1994): Immunohistochemical detection of mutant p53 protein in epithelial ovarian cancer using polyclonal antibody CMI: correlation with histopathology and clinical features. *Br. J. Cancer* 69: 609-612.
- ¹⁵⁰ **Henriksen**, R., Strang, P., Wilander, E., Bäckström, T., Tribukait, B., Öberg, K. (1994): p53 expression in epithelial ovarian neoplasms: relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry. *Gynecol Oncol* 53: 301-306.
- ¹⁵¹ **Kappes**, S., Milde-Langosch, K., Kressin, P., Passlack, B., Dockhorn-Dworniczak, B., Röhlke, P., Löning, T. (1995): p53 Mutations in ovarian tumors, detected by temperature-gradient gel electrophoresis, direct sequencing and immunohistochemistry. *Int. J. Cancer* 64: 52-59.

- ¹⁵² **Klemi**, P.-J., Pykkänen,L., Kiilholma,P., Kurvinen,K., Joensuu,H. (1995): p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. *Cancer* 76: 1201-1208.
- ¹⁵³ **Bosari**, S., Viale,G., Radaelli,U., Bossi,P., Bonoldi,E., Coggi,G. (1993): p53 accumulation in ovarian carcinomas and its prognostic implications. *Hum Pathol* 24: 1175-1179.
- ¹⁵⁴ **Niwa**, K., Itoh,M., Murase,T., Morishita, S., Itoh, N., Mori,G., Tamaya,T. (1994): Alteration of p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significance. *Br. J. Cancer* 70: 1191-1197.
- ¹⁵⁵ **Kim**, J.O., Cho,Y.H., Kwon,K.J., Kim,T.E., Park,T.C., Lee,J.M., Namkoong,S.E. (1995): Aberrations of the p53 tumor suppressor gene in human epithelial ovarian carcinoma. *Gynecologic Oncology* 57: 199-204.
- ¹⁵⁶ **Fléjou**, J.-F., Boulange,B., Bernades.P., Belghiti,J., Henin, D. (1996): p53 protein expression and DNA ploidy in cystic tumors of the pancreas. *Pancreas* 13: 247-252.
- ¹⁵⁷ **Yonezawa**,S., Sueyoshi,K., Nomoto,M., Kitamura,H., Nagata,K., Arimura,Y., Tanaka,S., Hollingsworth,M.A., Siddiki,B., Kim,Y.S., Sato,E. (1997):MUC2 gene expression is found in noninvasive tumors but not in invasive tumors of the pancreas and liver: close relationship with prognosis of the patients. *Hum Pathol* 28: 344-352.
- ¹⁵⁸ **Agrawal**, B., Gendler,S., Longenecker,M. (1998-1): The biological role of mucins in cellular interactions and immune regulation: prospects for cancer immunotherapy. *Mol. Med. today* 4: 397-403.
- ¹⁵⁹ **Spicer**, A.P., Rowse,G.J., Lidner,T.K., Gendler,S.J. (1995): Delayed mammary tumor progression in mUC-1 null mice. *J. Biol. Chem.* 270: 30093-30101.
- ¹⁶⁰ **Nakamori**, S., Ota,D.M., Cleary,K.R., Shirotani,K., Irimura,T. (1994): MUC1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma. *Gastroenterology* 106: 353-361.
- ¹⁶¹ **Reddish**, M.A., MacLean, G.D., Poppema,S., Berg, A., Longenecker, B.M. (1996): Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy. *Cancer Immunol Immunother* 42: 303-309.
- ¹⁶² **Dong**, Y., Walsh,M.,D., Cummings, M.C., Wright, R.G., Khoo, S.K., Parsons, P.G., McGuckin, M.A. (1997): Expression of MUC1 and MUC2 mucins in epithelial ovarian tumors. *J. Pathol* 183: 311-317.
- ¹⁶³ **McLean**, G.D., Reddish,M.A., Longenecker, B.M. (1997): Prognostic significance of preimmunotherapy serum CA 27.29 (MUC1) mucin level after active specific immunotherapy of metastatic adenocarcinoma patients. *J Immunother* 20: 70-78.
- ¹⁶⁴ **Hayes**, D.F., Silberstein, D.S., Rodrique, S.W., Kufe, D.W. (1990): DF3 antigen, a human epithelial cell mucin inhibits adhesion of eosinophils to antibody-coated targets. *J Immunol.* 145: 962-970.
- ¹⁶⁵ **Agrawal**, B., Krantz, M.J., Reddish, M., Longenecker, M.B. (1998-2): Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. *Nature med* 4: 43-49.
- ¹⁶⁶ **Hanski**, C., Drechsler, K., Hanisch,F.G., Sheehan, J., Manske,M., Ogorek, D., Klusmann, E., Hanski,M.L., Blank,M., Xing, P.X., McKenzie,I.F.c., Devine,P.L., Riecken, E.O. (1993): Altered glycolylation of the MUC-1 protein core contributes to the colon carcinoma-associated increase of mucin-bound sialyl-Lewis x expression.*Cancer Res.* 53: 4082-4088.
- ¹⁶⁷ **Hanski**,C., Hanski,M.-L., Zimmer,T., Ogorek,D, Devine,P., Riecken,E.-O. (1995): Characterization of the major sialyl-Lex-positive mucins present in colon, colon carcinoma and sera of patients with colorectal cancer. *Cancer Res.* 55: 928-933.
- ¹⁶⁸ **Varki**, A. (1994): Selectin ligands. *PNAS* 91: 7390-7397.
- ¹⁶⁹ **Sternberg**, L.R., Byrd, J.C., Yunker, C.K., Dudas, S., Hoon, V.K., Bresalier, R.S. (1999): Liver colonization by human colon cancer cells is reduced by antisense inhibition of MUC2 mucin synthesis. *Gastroenterol* 116: 363-371.
- ¹⁷⁰ **Okano**, K., Shimoda, T., Matsumura, Y. (1999): Clinicopathologic and immunogistochemical study of early colorectal cancer with liver metastases. *J Gastroenterol* 34: 334-340.

¹⁷¹ **Gourevitch**, M.M., von Mensdorff-Pouilly, S., Litvinov, S.V., Kenemans, P., van Kamp, G.J., Verstraeten, A.A., Hilgers, J. (1995): Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients. *Br. J. Cancer* 72: 934-938.

¹⁷² **Richards**, E.R., Devine, P.L., Quin, R.J., Fontenot, J.D., Ward, B.G., McGuckin, M.A. (1998): Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women. *Cancer Immunol Immunother* 46: 245-252.